GRCL
Gracell Biotechnologies Inc.
NASDAQ: GRCL · HEALTHCARE · BIOTECHNOLOGY
$10.25
+0.00% today
Updated 2026-06-05
Market cap
$989.87M
P/E ratio
—
P/S ratio
732.21x
EPS (TTM)
$-0.97
Dividend yield
—
52W range
$307 – $617
Volume
6.4M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.3
Quality
B+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →198 stocks currently score above 75
Price targets
Analyst target
$10.58
+3.22%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.07x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2020 | 2021 | 2022 | 2023 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $366000.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-197.16M | $-465.88M | $-607.51M | $-496.98M | $-496.98M |
| EPS | — | — | — | — | $-0.97 |
| Free cash flow | $-277.55M | $-361.29M | $-3.64B | — | — |
| Profit margin | — | -127,289.62% | — | — | — |
Peer comparison
Smart narrative
Gracell Biotechnologies Inc. trades at $10.25. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.
Frequently asked questions
What is Gracell Biotechnologies Inc.'s stock price?
Gracell Biotechnologies Inc. (GRCL) trades at $10.25, on a P/S of 732.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Gracell Biotechnologies Inc. overvalued?
Gracell Biotechnologies Inc. carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Gracell Biotechnologies Inc. (GRCL)?
The 12-month analyst consensus target is $10.58, about 3.2% above the current $10.25. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryChina
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio732.21x
ROE-30.66%
Beta-0.35
50D MA$9.54
200D MA$5.24
Shares out0.10B
Float0.17B
Short ratio—
Avg volume6.4M
Performance
1 week+0.00%
1 month+0.00%
3 months+0.00%
YTD+0.00%
1 year+0.00%
3 years—
5 years—